News

Therapeutic options and bladder-preserving strategies in bladder cancer reviewed

11 Apr 2014
Therapeutic options and bladder-preserving strategies in bladder cancer reviewed

Men are three to four times more likely to get bladder cancer than women.

The possible causes for this greater risk among men, the importance of early and accurate diagnosis, and the scope of available and emerging surgical, chemotherapeutic, and immunotherapeutic approaches for treating bladder cancer in men are the focus of a comprehensive Review article in Journal of Men’s Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

The article is available free on the Journal of Men’s Health website.

Coauthors R. Jeffrey Karnes, MD and Christopher Murphy, DO, Mayo Clinic (Rochester, MN), offer a detailed discussion of the three main types of malignancy that can derive from the epithelial lining of the bladder in the Review article Bladder Cancer in Males: A Comprehensive Review of Urothelial Carcinoma of the Bladder.

Each of these types of bladder cancer—nonmuscle-invasive, muscle-invasive, and metastatic—requires different management strategies.

Prompt diagnosis and appropriate surveillance for disease progression and recurrence are critical.

Source: AlphaGalileo